|
[1] World Health Organization. Global Tuberculosis Report 2017.[EB/OL]. http://www. who. int/tb/publications/global_report/en/.
|
|
[2] National Bureau of Statistics. Reports on morbidity and mortality of statutory category A and B infectious diseases[EB/OL]. http://data. stats. gov. cn/easyquery. htm? cn=C01. (in Chinese) 国家统计局.甲乙类法定传染病发病人数和死亡人数报告[EB/OL]. http://data. stats. gov. cn/easyquery. htm? cn=C01.
|
|
[3] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for hepatitis C:A 2015 update[J]. J Clin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015年更新版[J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.
|
|
[4] MO P, ZHU Q, TETER C, et al. Prevalence drug-induced hepatotoxicity and mortality among patients multi-infected with HIV tuberculosis and hepatitis virus[J]. Int J Infect Dis, 2014, 28:95-100.
|
|
[5] SHEN ER, ZHANG H, MA SW. Four clinical inconsistencies in tuberculosis patients coinfected with hepatitis B virus[J]. Chin Hepatol, 2016, 21 (11) :990-994. (in Chinese) 申恩瑞, 张慧, 马世武.结核菌和乙型肝炎病毒合并感染带来的四个临床矛盾[J].肝脏, 2016, 21 (11) :990-994.
|
|
[6] LOMTADZE N, KUPREISHVILI L, ALAKAIA A, et al. Hepatitis C virus co-infection increases the risk of anti-tuberculosis druginduced hepatotoxicity among patients with pulmonary tuberculosis[J]. PLo S One, 2013, 8 (12) :1-11.
|
|
[7] LU FF, TAN Y, FU ZX, et al. Rv2645 from mycobacterium tuberculosis RD13 region promoters ISG15 expression and overexpression of ISG15 enhances HCV replication in vitro[J]. Chin J Virol, 2017, 33 (3) :372-379. (in Chinese) 卢芳芳, 谭杨, 付忠晓, 等.结核分枝杆菌RV2645刺激ISG15的表达上升促进体外丙型肝炎病毒的增殖[J].病毒学报, 2017, 33 (3) :372-379.
|
|
[8] SIRINAK C, KITTIKRAISAK W, PINJEESEKIKUL D, et al. Viral hepatitis and HIV-associated tuberculosis:Risk factors and TB treatment outcomes in Thailand[J]. BMC Public Health, 2008, 8 (1) :245-245.
|
|
[9] REIS NR, LOPES CL, TELES SA, et al. Hepatitis C virus infection in patients with tuberculosis in Central Brazil[J]. Int J Tuberc Lung Dis, 2011, 15 (10) :1397-1402.
|
|
[10] BUSHNELL G, STENNIS NL, DROBNIK AM, et al. Characteristics and TB treatment outcomes in TB patients with viral hepatitis, New York City, 2000-2010[J]. Epidemiol Infect, 2015, 143 (9) :1972-1981.
|
|
[11] GU JY, ERXIDING MMT, XIANG Y, et al. The analysis of distribution and associated liver damage in patient with tuberculosis and underlying hepatitis C[J]. Chin J Dis Control Prev, 2015, 19 (2) :119-122. (in Chinese) 顾佳怡, 尔西丁·买买提, 向阳, 等.肺结核病人中丙型肝炎分布特征及其与肝功能损害的关联性分析[J].中华疾病控制杂志, 2015, 19 (2) :119-122.
|
|
[12] WANG JY, LIU CH, HU FC, et al. Risk factors of hepatitis during Anti-tuberculous treatment and implications of hepatitis virus load[J]. J Infect, 2011, 62 (6) :448-455.
|
|
[13] WU PH, LIN YT, HSIEH KP, et al. Hepatitis C virus infection is associated with an increased risk of active tuberculosis disease a nationwide population-based study[J]. Medicine, 2015, 94 (33) :e1328.
|
|
[14] KUNIHOLM MH, MARK J, ALADASHVILI M, et al. Risk factors and algorithms to identify hepatitis C, hepatitis B, and HIV among Georgian tuberculosis patients[J]. Int J Infect Dis, 2008, 12 (1) :51-56.
|
|
[15] LIU D, LIU Y, HUANG FX, et al. Hepatitis C antibody test results:Analysis of 2 947 patients with tuberculosis (TB) [J]. J Pathog Biol, 2012, 7 (11) :insert 2-3. (in Chinese) 刘丹, 刘艳, 黄费湘, 等. 2947例结核 (TB) 患者丙型肝炎病毒抗体检测结果分析[J].中国病原生物学杂志, 2012, 7 (11) :附页2-3.
|
|
[16] CAMPO M, SHRESTHA A, ORENO E, et al. Characterization of hepatitis C infection in tuberculosis patients in an urban city in the USA[J]. Epidemiol Infect, 2014, 142 (7) :1459-1466.
|
|
[17] CHENG XZ, LI WB, ZHANG H, et al. Investigation in tuberculosis patients combined with hepatitis or other infectious diseases[J].Henan J Prevent Med, 2015, 26 (1) :42-46. (in Chinese) 程新征, 李卫彬, 张辉, 等.肺结核患者合并肝炎等传染性疾病调查分析[J].河南预防医学杂志, 2015, 26 (1) :42-46.
|
|
[18] NOOREDINVAND HA, CONNELL DW, ASGHEDDI M, et al.Viral hepatitis prevalence in patients with active and latent tuberculosis[J]. World J Gastroenterol, 2015, 21 (29) :8920-8926.
|
|
[19] MERZA MA, HAJI SM, ALSHARAFANI AM, et al. Low prevalence of hepatitis B and C among tuberculosis patients in Duhok Province, Kurdistan:Are HBs Ag and anti-HCV prerequisite screening parameters in tuberculosis control program[J]. Int J Mycobacteriol, 2016, 5 (3) :313-317.
|
|
[20] COSTI C, GRANDI T, HALON ML, et al. Prevalence of hepatitis C virus and human immunodeficiency virus in a group of patients newly diagnosed with active tuberculosis in Porto Alegre, Southern Brazil[J]. Mem Inst Oswaldo Cruz, 2017, 112 (4) :255-259.
|
|
[21] LI JL, SHANG J, NING HB. Management and treatment of special populations with hepatitis C virus infection in the era of direct-acting antiviral agents[J]. J Clin Hepatol, 2018, 34 (2) :242-245. (in Chinese) 李俊利, 尚佳, 宁会彬.直接抗病毒药物时代特殊人群HCV感染的管理和治疗[J].临床肝胆病杂志, 2018, 34 (2) :242-245.
|
|
[22] KIRBY BJ, SYMONDS WT, KEARNEY BP, et al. Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B poly-merase inhibitor sofosbuvir[J]. Clin Pharmacokinet, 2015, 54 (7) :677-690.
|
|
[23] MARRA F, GERMAN P, PANG P, et al. Drug-drug interaction profile, including HIV ART, of the HCV fixed-dose combination tablet ledipasvir/sofosbuvir[J]. Hiv Med, 2015, 16:35-35.
|
|
[24] SEKAR V, VERLOES R, MEYVISCH P, et al. Evaluation of metabolic interactions for TMC435 via cytochrome P450 (CYP) enzymes in healthy volunteers[J]. J Hepatol, 2010, 52 (Suppl 1) :416-416.
|
|
[25] ZHOU SN, ZHANG M. Metabolism and drug interactions of direct-acting antiviral agents for hepatitis C[J]. Infect Dis Inf, 2016, 29 (2) :121-125. (in Chinese) 周双男, 张敏.丙型肝炎直接抗病毒药物的代谢及药物相互作用[J].传染病信息, 2016, 29 (2) :121-125.
|
|
[26] HEP Drug Interactions, 2018[EB/OL]. http://hep-druginteractions. org.
|
|
[27] Up To Data websute[EB/OL]. http://www. uptodate. com.
|
|
[28] XUE XP, GUO XL, WANG LP. Clinical research on combined therapy of interferon and ribavirin for hepatitis C cirrhosis[J]. Int J Virol, 2016, 23 (2) :127-129. (in Chinese) 薛小萍, 郭晓莉, 王丽萍.干扰素联合利巴韦林治疗丙肝肝硬化的临床研究[J].国际病毒学杂志, 2016, 23 (2) :127-129.
|
|
[29] MATSUOKA S, FUJIKAWA H, HASEGAWA H, et al. Onset of tuberculosis from a pulmonary latent tuberculosis infection during antiviral triple therapy for chronic hepatitis C[J]. Intern Med, 2016, 55 (15) :2011-2017.
|
|
[30] ABUTIDZE A, BOLOKADZ N, CHKHARTISHVILI N, et al. Incidence of tuberculosis among HIV/HCV coinfected patients receiving hepatitis C treatment with pegylated interferon and ribavirin in Georgia[J]. Georgian Med News, 2016, (252) :10-15.
|
|
[31] LIN SY, CHEN TC, LU PL, et al. Incidence rates of tuberculosis in chronic hepatitis C infected patients with or without interferon based therapy:A population-based cohort study in Taiwan[J].BMC Infect Dis, 2014, 14 (1) :705.
|
|
[32] BABUDIERI S, SODDU A, MURINO M, et al. Tuberculosis screening before anti-hepatitis C virus therapy in prisons[J]. Emerg Infect Dis, 2012, 18 (4) :689-691.
|
|
[33] SABBATANI S, MANFREDI R, MARINACCI G, et al. Reactivation of severe acute pulmonary tuberculosis during treatment with pegylated interferon-alpha and ribavirin for chronic HCV hepatitis[J]. Scand Infect Dis, 2006, 38 (3) :205-208.
|
|
[34] TELESCA C, ANGELICO M, PICCOLO P, et al. Interferon-alpha treatment of hepatitis D induces tuberculosis exacerbation in an immigrant[J]. J Infect, 2007, 54 (4) :223-226.
|
|
[35] SENOUSY B, BELAL S, DRAGANOY P, et al. Hepatotoxic effects of therapies for tuberculosis[J]. Nat Rev Gastroenterol Hepatol, 2010, 7 (10) :543-546.
|
|
[36] BOUAZZI O, HAMMI S, BOURKADI J, et al. First line anti-tuberculosis induced hepatotoxicity:Incidence and risk factors[J].Pan Afr Med, 2016, 16 (25) :167.
|
|
[37] Chinese Society for Tuberculosis, Chinese Medical Association. Expert recommendations on diagnosis and treatment of anti-tuberculosis liver injury[J]. Chin J Tuberc Respir Dis, 2013, 36 (10) :732-736. (in Chinese) 中华医学会结核病学分会.抗结核药所致药物性肝损伤诊断与处理专家建议[J].中华结核和呼吸杂志, 2013, 36 (10) :732-736.
|
|
[38] ZHOU Y, YANG L, LIAO Z, et al. Epidemiology of drug-induced liver injury in China:A systematic analysis of the Chinese literature including 21, 789 patients[J]. Eur J Gastroenterol Hepatol, 2013, 25 (7) :825-829.
|
|
[39] SHANG P, XIA Y, LIU F, et al. Incidence clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China[J]. PLo S One, 2011, 6 (7) :e21836.
|
|
[40] KIM WS, LEE SS, LEE CM, et al. Hepatitis C and not hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury[J]. BMC Infect Dis, 2016, 16 (1) :50.
|
|
[41] TSAI MC, LIN MC, HUNG CH. Successful antiviral and antituberculosis treatment with pegylated interferon-alfa and ribavirin in a chronic hepatitis C patient with pulmonary tuberculosis[J]. Formos Med Assoc, 2009, 108 (9) :746-750.
|
|
[42] WU Z, HUO N, LI J, et al. Advances in the diagnosis and therapy of hepatitis C virus reactivation[J]. Chin J Pract Intern Med, 2016, 36 (3) :212-215. (in Chinese) 吴朝, 霍娜, 李俊, 等.丙型肝炎病毒再激活诊疗进展[J].中国实用内科杂志, 2016, 36 (3) :212-215.
|
|
[43] CIESEK S, STEINMANN E, IKEN M, et al. GIucocorticosteroid increase cell entry by hepatitis C virus[J]. Gastroenterology, 2010, 138 (5) :1875-l884.
|
|
[44] CHEN MH, CHEN MH, TSAI CY, et al. Incidence and antiviral response of hepatitis C virus reactivation in lupus patients undergoing immunosuppressive therapy[J]. Lupus, 2015, 24 (10) :1029-1036.
|
DownLoad: